Nektar Therapeutics (NKTR) Net Margin (2010 - 2026)

Nektar Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 397.33% for Q1 2026.

• In Q1 2026, Net Margin rose 4647.0% year-over-year to 397.33%; the TTM figure through Mar 2026 stood at 273.37% (down 12598.0% YoY), while the FY2025 annual figure was 281.27%, down 16039.0% from the prior year.
• Net Margin was 397.33% for Q1 2026 at Nektar Therapeutics, down from 159.27% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 24.85% in Q4 2024 to a low of 736.94% in Q2 2022.
• Historically, Net Margin has averaged 296.3% across 5 years, with a median of 249.94% in 2022.
• The sharpest annual moves came in 2022 and 2023: Net Margin plunged 29388 bps in 2022, then soared 48755 bps in 2023.
• A 5-year view of Net Margin shows it stood at 271.03% in 2022, then surged by 37 bps to 171.49% in 2023, then soared by 114 bps to 24.85% in 2024, then plunged by 741 bps to 159.27% in 2025, then plunged by 149 bps to 397.33% in 2026.
• The last three Net Margin figures came in at 397.33% (Q1 2026), 159.27% (Q4 2025), and 296.76% (Q3 2025), per Business Quant data.